The humoral response to human factor VIII in hemophilia A mice

被引:38
作者
Healey, J. F.
Parker, E. T.
Barrow, R. T.
Langley, T. J.
Church, W. R.
Lollar, P.
机构
[1] Childrens Healthcare Atlanta, Aflac Canc Ctr, Dept Pediat, Atlanta, GA USA
[2] Childrens Healthcare Atlanta, Blood Disorders Serv, Dept Pediat, Atlanta, GA USA
[3] Emory Univ, Atlanta, GA 30322 USA
[4] Green Mt Antibodies, Burlington, VT USA
关键词
factor VIII; hemophilia A; immunogenicity; inhibitor;
D O I
10.1111/j.1538-7836.2007.02373.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Inhibitory antibodies (Abs) to factor VIII (FVIII inhibitors) constitute the most significant complication in the management of hemophilia A. The analysis of FVIII inhibitors is confounded by polyclonality and the size of FVIII. Objectives: The goal of this study was to dissect the polyclonal response to human FVIII in hemophilia A mice undergoing a dosage schedule that mimics human use. Methods: Splenic B-cell hybridomas were obtained following serial i.v. injections of submicrogram doses of FVIII. Results of a novel, anti-FVIII domain-specific enzyme-linked immunosorbent assay were compared to Ab isotype and anti-FVIII inhibitory activity. Results: The robust immune response resulted in the production of similar to 300 hybridomas per spleen. We characterized Abs from 506 hybridomas, representing the most comprehensive analysis of a protein antigen to date. Similar to the human response to FVIII, anti-A2 and anti-C2 Abs constituted the majority of inhibitors. A novel epitope was identified in the A2 domain by competition ELISA. Anti-A2 and anti-C2 Abs were significantly associated with IgG(1) and IgG(2a) isotypes, respectively. Because the IgG(2a) isotype is associated with enhanced Fc receptor-mediated effector mechanisms, this result suggests that anti-C2 Abs and inflammation may be linked. Additionally, we identified a novel class of Abs with dual specificity for the A1 and A3 domains. Forty per cent of the Abs had no detectable inhibitory activity, indicating that they are prominent and potentially pathologically significant. Conclusion: The expanded delineation of the humoral response to FVIII may lead to improved management of hemophilia A through mutagenesis of FVIII B-cell epitopes.
引用
收藏
页码:512 / 519
页数:8
相关论文
共 35 条
[1]   MOLECULAR-BASIS OF FACTOR-VIII INHIBITION BY HUMAN-ANTIBODIES - ANTIBODIES THAT BIND TO THE FACTOR-VIII LIGHT CHAIN PREVENT THE INTERACTION OF FACTOR-VIII WITH PHOSPHOLIPID [J].
ARAI, M ;
SCANDELLA, D ;
HOYER, LW .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 83 (06) :1978-1984
[2]   Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules [J].
Barrow, RT ;
Healey, JF ;
Gailani, D ;
Scandella, D ;
Lollar, P .
BLOOD, 2000, 95 (02) :564-568
[3]   TARGETED DISRUPTION OF THE MOUSE FACTOR-VIII GENE PRODUCES A MODEL OF HEMOPHILIA-A [J].
BI, L ;
LAWLER, AM ;
ANTONARAKIS, SE ;
HIGH, KA ;
GEARHART, JD ;
KAZAZIAN, HH .
NATURE GENETICS, 1995, 10 (01) :119-121
[4]   Sustained expression of therapeutic levels of human factor VIII in mice [J].
Connelly, S ;
Gardner, JM ;
Lyons, RM ;
McClelland, A ;
Kaleko, M .
BLOOD, 1996, 87 (11) :4671-4677
[5]   High level expression of recombinant porcine coagulation factor VIII [J].
Doering, CB ;
Healey, JF ;
Parker, ET ;
Barrow, RT ;
Lollar, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (41) :38345-38349
[6]  
Doering CB, 2002, THROMB HAEMOSTASIS, V88, P450
[7]   Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa [J].
Fay, PJ ;
Scandella, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (42) :29826-29830
[8]   Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcγ receptor III [J].
Fossati-Jimack, L ;
Ioan-Facsinay, A ;
Reininger, L ;
Chicheportiche, Y ;
Watanabe, N ;
Saito, T ;
Hofhuis, FMA ;
Gessner, JE ;
Schiller, C ;
Schmidt, RE ;
Honjo, T ;
Verbeek, JS ;
Izui, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (08) :1293-1302
[9]   RESIDUES 484-508 CONTAIN A MAJOR DETERMINANT OF THE INHIBITORY EPITOPE IN THE A2 DOMAIN OF HUMAN FACTOR-VIII [J].
HEALEY, JF ;
LUBIN, IM ;
NAKAI, H ;
SAENKO, EL ;
HOYER, LW ;
SCANDELLA, D ;
LOLLAR, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (24) :14505-14509
[10]  
Hoyer L W, 1984, Prog Clin Biol Res, V150, P73